Clinical study of the effect of levosimendan on Cleveland score-based cardiac surgery-related AKI (CSA-AKI)

Clinical study of the effect of levosimendan on Cleveland score-based cardiac surgery-related AKI (CSA-AKI).

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034950

Enrollment

Unknown

Registered

2020-07-25

Start date

2020-07-13

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac surgery-associated acute kidney injury

Interventions

Trial Group:Levosimendan + standard inotropic medication

Control Group:standard inotropic medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cardiopulmonary bypass patients in cardiac surgery; 2. Cleveland score 3-8; 3. Extracorporeal circulation time >=140 min; 4. Aged >= 18 and <= 65 years; 5. Signing of informed consent;

Exclusion criteria

Exclusion criteria: 1. Those who have used levosimendan within 30 days; 2. Pregnant and lactating women; 3. Patients with cirrhosis; Renal replacement therapy was performed before operation; 4. Those who have participated in other clinical trials within 30 days; 5. Incomplete information.

Design outcomes

Primary

Measure	Time frame
RRTusage;	—

Secondary

Measure	Time frame
Incidence of CSA-AKI;28-day mortality;Mechanical ventilation time;ICU Time;Infection rate;ICU mortality;In-hospital mortality;	—

Countries

China

Contacts

Public ContactWang Cuiping

The First Affiliated Hospital of Sun Yat-Sen University

14316310@qq.com+86 020-87755766-8254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026